Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Short term Debt (2016 - 2025)

Sanofi (SNY) has disclosed Short term Debt for 11 consecutive years, with $5.1 billion as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 12.37% to $5.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.1 billion through Dec 2025, up 12.37% year-over-year, with the annual reading at $4.9 billion for FY2025, 7.68% up from the prior year.
  • Short term Debt hit $5.1 billion in Q4 2025 for Sanofi, up from $4.5 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $5.1 billion in Q4 2025 to a low of $2.2 billion in Q4 2023.
  • Historically, Short term Debt has averaged $3.9 billion across 5 years, with a median of $4.3 billion in 2022.
  • Biggest five-year swings in Short term Debt: plummeted 48.33% in 2023 and later skyrocketed 104.41% in 2024.
  • Year by year, Short term Debt stood at $3.6 billion in 2021, then rose by 16.95% to $4.3 billion in 2022, then plummeted by 48.33% to $2.2 billion in 2023, then soared by 104.41% to $4.5 billion in 2024, then increased by 12.37% to $5.1 billion in 2025.
  • Business Quant data shows Short term Debt for SNY at $5.1 billion in Q4 2025, $4.5 billion in Q4 2024, and $2.2 billion in Q4 2023.